Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06966674
NA
No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
Sponsor: Kafrelsheikh University
View on ClinicalTrials.gov
Summary
This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.
Official title: Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-05-12
Completion Date
2025-10-01
Last Updated
2025-05-13
Healthy Volunteers
No
Conditions
Interventions
DRUG
Intracoronary tirofiban
Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg).
DRUG
Saline 0.9%
Patients will receive intracoronary saline 0.9% solution as a control group.
Locations (1)
Kafrelsheikh University
Kafr ash Shaykh, Kafrelsheikh, Egypt